AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 37648417
Drug: Short oral/two-step
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short oral/two-step consent (SOC)
Trial: 37648579
Drug: Dapagliflozin 10
RxNorm normalized name: dapagliflozin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapagliflozin 10 mg once daily in addition to standard of care therapy
Trial: 37649617
Drug: Moderna mRNA-1273
RxNorm normalized name: MRNA-1273 SARS-COV-2
DrugBank: Moderna COVID-19 Vaccine (DB15654)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderna mRNA-1273 vaccine
Trial: 37650231
Drug: Novel therapeutics
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Novel therapeutics for the treatment of early COVID-19, specific interventions not detailed.
Trial: 37650230
Drug: Monoclonal antibodies
RxNorm normalized name: Monoclonal antibodies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monoclonal antibodies (mAbs)
Trial: 37650234
Drug: Investigational agents
RxNorm normalized name: INVESTIGATIONAL AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational agents (specific agents not detailed)
Trial: 37650235
Drug: Antiviral treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiviral treatment in outpatient trials
Trial: 37650754
Drug: Microablative fractional
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microablative fractional CO laser treatment
Trial: 37650759
Drug: Yellow fever
RxNorm normalized name: yellow fever live
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yellow fever vaccine (17DD)
Trial: 37650808
Drug: Best-practices Treatment
RxNorm normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Best-practices Treatment as Usual (TAU)
Trial: 37651373
Drug: High-dose TXA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose TXA (20 mg/kg loading dose followed by 5 mg/kg/h continuous infusion)
Trial: 37651373
Drug: Low-dose TXA
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose TXA (20 mg/kg loading dose followed by continuous infusion of normal saline)
Trial: 37651654
Drug: Interval-compressed chemotherapy
RxNorm normalized name: Ulva compressa extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interval-compressed chemotherapy
Trial: 37651655
Drug: Tisotumab vedotin
RxNorm normalized name: Tisotumab vedotin
DrugBank: Tisotumab vedotin (DB16732)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tisotumab vedotin (TV) + Carboplatin (1L treatment); TV 2 mg/kg + Carboplatin AUC 5 on day 1 every 3 weeks
Trial: 37651655
Drug: Tisotumab vedotin
RxNorm normalized name: Tisotumab vedotin
DrugBank: Tisotumab vedotin (DB16732)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tisotumab vedotin (TV) + Pembrolizumab (1L treatment); TV 2 mg/kg + Pembrolizumab 200 mg on day 1 every 3 weeks
Trial: 37651655
Drug: Tisotumab vedotin
RxNorm normalized name: Tisotumab vedotin
DrugBank: Tisotumab vedotin (DB16732)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tisotumab vedotin (TV) + Pembrolizumab (2L/3L treatment); TV 2 mg/kg + Pembrolizumab 200 mg on day 1 every 3 weeks
Trial: 37651655
Drug: Tisotumab vedotin
RxNorm normalized name: Tisotumab vedotin
DrugBank: Tisotumab vedotin (DB16732)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tisotumab vedotin (TV) + Bevacizumab; TV 2 mg/kg + Bevacizumab 15 mg/kg on day 1 every 3 weeks
Trial: 37651676
Drug: Nivolumab (NIVO)
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nivolumab (NIVO) monotherapy
Trial: 37651844
Drug: Oral fumarate
RxNorm normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral fumarate therapy
Trial: 37652094
Drug: Local budesonide
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Local budesonide therapy (budesonide and physiological saline nasal irrigations administered via three syringes of 20 ml in each nasal cavity in the morning and evening for 30 days)
Trial: 37652356
Drug: Vaccine Acceptance
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine Acceptance Intervention (VAI) training
Trial: 37652554
Drug: Ustekinumab (UST)
RxNorm normalized name: Ustekinumab
DrugBank: Ustekinumab (DB05679)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ustekinumab (UST) 6 mg/kg intravenous at week 0 followed by 90 mg subcutaneous every 8 weeks from week 8 to week 24
Trial: 37652940
Drug: HMO-Concentrate administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HMO-Concentrate administered orally for 7 days
Trial: 37653140
Drug: Bispecific antibodies
RxNorm normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bispecific antibodies targeting GPRC5D
Trial: 37653215
Drug: GLP-1RA +
RxNorm normalized name: IL-1RA
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: GLP-1RA + Met (liraglutide, 1.2-1.8 mg/day + Met 1500 mg/day)
Trial: 37653215
Drug: CPA/EE +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPA/EE + Met (2 mg/day CPA and 35 μg EE + Met 1500 mg/day)
Trial: 37653218
Drug: Prophylactic low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Prophylactic low-dose hydrocortisone (HC)
Trial: 37653525
Drug: High-Intensity Laser
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-Intensity Laser Therapy (HILT) and stretching exercises
Trial: 37653525
Drug: Sham High-Intensity
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham High-Intensity Laser Therapy (sham HILT) and stretching exercises
Trial: 37653536
Drug: Mother-Child Emotional
RxNorm normalized name: Senna-Relief Childs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mother-Child Emotional Preparation (MCEP)
Trial: 37653768
Drug: PP6M (700/1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PP6M (700/1000 mg eq.)
Trial: 37653768
Drug: PP3M (350/525
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PP3M (350/525 mg eq.)
Trial: 37654659
Drug: Non-invasive physical
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-invasive physical plasma (NIPP) treatment
Trial: 37654668
Drug: Monoclonal antibody
RxNorm normalized name: Monoclonal antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monoclonal antibody treatment
Trial: 37654668
Drug: Corticosteroids therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroids therapy for mild/severe cases
Trial: 37654668
Drug: Early treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early treatment with monoclonal Ab
Trial: 37654895
Drug: Acetaminophen (APAP)
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen (APAP) + anti-PD-1 treatment (sintilimab)
Trial: 37654895
Drug: Anti-PD-1 treatment
RxNorm normalized name: Dianeal PD-2/1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-PD-1 treatment (sintilimab) alone
Trial: 37654895
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of APAP and anti-PD-1 treatment
Trial: 37655106
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy (13 patients)
Trial: 37655106
Drug: Neoadjuvant immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant immunotherapy (26 patients)
Trial: 37655205
Drug: selpercatinib treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: selpercatinib treatment
Trial: 37655258
Drug: Percutaneous coronary
RxNorm normalized name: Glebionis coronaria whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Percutaneous coronary intervention in addition to optimal medical therapy
Trial: 37656413
Drug: Compound Danshen
RxNorm normalized name: DANSHEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compound Danshen Dripping Pills (CDDP) - 20 tablets before pPCI and 10 tablets 3 times daily after pPCI
Trial: 37656413
Drug: Compound Danshen
RxNorm normalized name: DANSHEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compound Danshen Dripping Pills (CDDP)
Trial: 37656441
Drug: Anti-IL6-directed therapy
RxNorm normalized name: DIRECT BLUE 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-IL6-directed therapy (siltuximab or tocilizumab)
Trial: 37656948
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy followed by surgery (NACT-S), n = 314
Trial: 37657279
Drug: Usual Community
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual Community Care (CC)
Trial: 37657460
Drug: TTFields therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TTFields therapy with standard systemic therapy (investigator's choice of immune checkpoint inhibitor or docetaxel)
Trial: 37856212
Drug: Standard systemic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard systemic therapy alone
Trial: 37657460
Drug: TTFields therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TTFields therapy with standard systemic therapy
Trial: 37657460
Drug: TTFields therapy-related
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TTFields therapy-related adverse events
Trial: 37657463
Drug: Adenoviral vectors
RxNorm normalized name: COVID-19 VACCINE ADENOVIRUS-26
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adenoviral vectors expressing HSV1-TK and Flt3L, administered via injections into the tumor bed after maximal safe resection, with six escalating doses starting from 1×10 (exact dosage not specified).
Trial: 37657463
Drug: Adenoviral vectors
RxNorm normalized name: COVID-19 VACCINE ADENOVIRUS-26
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adenoviral vectors expressing HSV1-TK and Flt3L (combined treatment).
Trial: 37657522
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of 0.125 M L-glutamic acid at 1.65 mL/kg/h for 150 min before reperfusion
Trial: 37657522
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of 0.125 M L-glutamic acid
Trial: 37657525
Drug: TwHF monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TwHF monotherapy
Trial: 37657523
Drug: Oligofructose 8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oligofructose 8 g/d (plus 2 g/d maltodextrin)
Trial: 37657523
Drug: Oligofructose 8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oligofructose 8 g/d plus 2'fucosyllactose (2 g/d)
Trial: 37657523
Drug: 2'fucosyllactose 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2'fucosyllactose 2 g/d (plus 8 g/d maltodextrin)
Trial: 37657523
Drug: Maltodextrin 10
RxNorm normalized name: maltodextrin 100 % MISCELL POWDER (GRAM)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maltodextrin 10 g/d
Trial: 37657768
Drug: Atrasentan (endothelin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atrasentan (endothelin receptor antagonist)
Trial: 37657939
Drug: Neflamapimod 40
RxNorm normalized name: Neflamapimod
DrugBank: Neflamapimod (DB07138)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neflamapimod 40 mg three times daily (TID)
Trial: 37658083
Drug: Atezolizumab (1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atezolizumab (1200 mg)
Trial: 37658272
Drug: NCT (Neoadjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NCT (Neoadjuvant Chemotherapy)
Trial: 37658468
Drug: Allogeneic adipose-derived
RxNorm normalized name: human adipose preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allogeneic adipose-derived mesenchymal stem cell (ASC) injection into the submandibular glands (n=60)
Trial: 37658468
Drug: Placebo injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo injection (CryoStor10, n=60)
Trial: 37658603
Drug: HSV-1-targeting CRISPR
RxNorm normalized name: HSV-1 G207
DrugBank: G207 (DB05827)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HSV-1-targeting CRISPR formulation
Trial: 37659025
Drug: Nivolumab plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab plus ipilimumab (adjuvant therapy)
Trial: 37659283
Drug: Prednisone 40
RxNorm normalized name: prednisone 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone 40 mg per day for one week
Trial: 37659673
Drug: Guselkumab 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guselkumab 400 mg
Trial: 37659673
Drug: Guselkumab 200
RxNorm normalized name: guselkumab 200 MG in 20 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guselkumab 200 mg (nonresponders at week 12)
Trial: 37659673
Drug: Guselkumab 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guselkumab 400 mg (nonresponders at week 12)
Trial: 37660042
Drug: Control (Medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (Medication and Traditional Physiotherapy)
Trial: 37660052
Drug: 0.2 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg/kg dexamethasone
Trial: 37660535
Drug: PD-1-based immunotherapy
RxNorm normalized name: Dianeal PD-2/1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PD-1-based immunotherapy with tumor PD-L1 determined in lymph node metastases
Trial: 37660535
Drug: PD-1-based immunotherapy
RxNorm normalized name: Dianeal PD-2/1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PD-1-based immunotherapy with tumor PD-L1 determined in primary tumors
Trial: 37660535
Drug: PD-1-based immunotherapy
RxNorm normalized name: Dianeal PD-2/1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PD-1-based immunotherapy with tumor PD-L1 determined in skin/subcutaneous metastases
Trial: 37660704
Drug: Placebo/Weekly dupilumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo/Weekly dupilumab
Trial: 37660711
Drug: V160 three-dose
RxNorm normalized name: THREE-LOBE SAGE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: V160 three-dose regimen (V160 at day 1, month 2, and month 6)
Trial: 37660711
Drug: V160 two-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: V160 two-dose regimen (V160 on day 1, placebo at month 2, and V160 at month 6)
Trial: 37660711
Drug: Placebo (saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (saline solution at day 1, month 2, and month 6)
Trial: 37660711
Drug: V160 three-dose
RxNorm normalized name: THREE-LOBE SAGE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: V160 three-dose regimen
Trial: 37660711
Drug: V160 two-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: V160 two-dose regimen
Trial: 37660952
Drug: Automated Self-Administered
RxNorm normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Automated Self-Administered 24-h recalls (ASA24s)
Trial: 37661107
Drug: Intraduodenal infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraduodenal infusion of glucose (22.5 g, 1 kcal/min) and oleic acid (10 g, 1 kcal/min) for 90 min
Trial: 37661107
Drug: Intraduodenal infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraduodenal infusion with benzocaine
Trial: 37661107
Drug: Intraduodenal nutrient
RxNorm normalized name: Votrient
DrugBank: Pazopanib (DB06589)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intraduodenal nutrient infusion
Trial: 37662520
Drug: Parsaclisib 20
RxNorm normalized name: Parsaclisib
DrugBank: Parsaclisib (DB14867)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parsaclisib 20 mg once daily for 8 weeks then 2.5 mg QD (daily dosing group [DG])
Trial: 37662520
Drug: Parsaclisib 20
RxNorm normalized name: Parsaclisib
DrugBank: Parsaclisib (DB14867)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parsaclisib 20 mg once daily for 8 weeks then 20 mg once weekly (weekly dosing group [WG])
Trial: 37662595
Drug: sucrosomial Vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sucrosomial Vitamin D3 (200,000 IU weekly)
Trial: 37662595
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 treatment (not specified)
Trial: 37663359
Drug: Informative booklet
RxNorm normalized name: INFORMATION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Informative booklet and weekly phone calls for 6 weeks
Trial: 37663593
Drug: Electroacupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electroacupuncture treatment (EA) using sacral acupoints
Trial: 37663593
Drug: Electroacupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electroacupuncture treatment (EA) using abdominal acupoints
Trial: 37663593
Drug: Electroacupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electroacupuncture treatment (EA) using alternating acupoints
Trial: 37663593
Drug: Electroacupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electroacupuncture treatment (EA)
Trial: 37664025
Drug: Lenvatinib (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenvatinib (20 mg/day) plus Pembrolizumab (200 mg every 3 weeks)
Trial: 37664025
Drug: Sunitinib (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib (50 mg/day, 4 weeks on, 2 weeks off)
Trial: 37664560
Drug: Standard pfCa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard pfCa monitoring (aiming pfCa level of 0.25-0.35 mmol/L)
Trial: 37664560
Drug: No pfCa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No pfCa monitoring (constant citrate infusion at 4 mmol/L)
Trial: 37665178
Drug: Selinexor 40
RxNorm normalized name: selinexor 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selinexor 40 mg/m2 with mitoxantrone, etoposide, and cytarabine (MEC)
Trial: 37665397
Drug: Dexmedetomidine (0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (0.15 µg kg continuous intravenous infusion)
Trial: 37665497
Drug: Preservative-free oxybuprocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preservative-free oxybuprocaine hydrochloride 0.4% unit-dose eye drops, five times daily postoperatively until complete epithelial healing
Trial: 37665565
Drug: Governmental non-pharmaceutical
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Governmental non-pharmaceutical interventions (NPI's)
Trial: 37665877
Drug: General American
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General American College of Sports Medicine exercise prescription
Trial: 37666264
Drug: Regorafenib combined
RxNorm normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Regorafenib combined with nivolumab and FOLFOX chemotherapy
Trial: 37666539
Drug: Olvimulogene nanivacirepvec
RxNorm normalized name: Olvimulogene nanivacirepvec
DrugBank: Olvimulogene nanivacirepvec (DB16268)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olvimulogene nanivacirepvec (Olvi-Vec) followed by platinum-doublet chemotherapy and bevacizumab
Trial: 37666539
Drug: Platinum-doublet chemotherapy
RxNorm normalized name: platinum
DrugBank: Platinum (DB12257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platinum-doublet chemotherapy and bevacizumab
Trial: 37667204
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose primaquine
Trial: 37667213
Drug: L-PRF +
RxNorm normalized name: L-377202
DrugBank: L-377202 (DB19022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-PRF + Collagen Membrane (CM)
Trial: 37667507
Drug: HLA fully-mismatched
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HLA fully-mismatched sibling-derived CD7 CAR-T therapy
Trial: 37667847
Drug: 9-valent human
RxNorm normalized name: L1 protein, human papillomavirus type 31 vaccine
DrugBank: Human papillomavirus type 31 L1 capsid protein antigen (DB10310)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9-valent human papillomavirus (9vHPV) vaccine
Trial: 37668289
Drug: Canakinumab 150
RxNorm normalized name: canakinumab 150 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Canakinumab 150 or 300 mg, either every 4 weeks or every 8 weeks, with up-titration permitted after on-treatment flares (maximum dose: 300 mg q4w)
Trial: 37668289
Drug: Canakinumab 150
RxNorm normalized name: canakinumab 150 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Canakinumab 150 or 300 mg
Trial: 37668898
Drug: AK120 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AK120 600 mg single ascending dose (SAD) in healthy subjects
Trial: 37668898
Drug: AK120 multiple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AK120 multiple ascending doses (300 mg Q2W, 300 mg QW, 150 mg QW, 75 mg QW) in subjects with AD
Trial: 37669277
Drug: Pharmaceutical education
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pharmaceutical education about the correct use of antibiotic/s
Trial: 37669281
Drug: Mindfulness-Based Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness-Based Cognitive Therapy (MBCT) plus Supported Protocolized Discontinuation (SPD)